Dorzolamide-timolol reduces IOP better than brimonidine after phaco

Article

Prophylactic treatment with dorzolamide-timolol fixed combination is more effective than brimonidine in reducing IOP after phacoemulsification surgery, claims a study published in the January issue of Eye & Contact Lens: Science & Clinical Practice.

Prophylactic treatment with dorzolamide-timolol fixed combination is more effective than brimonidine in reducing IOP after phacoemulsification surgery, claims a study published in the January issue of Eye & Contact Lens: Science & Clinical Practice.

Yelda Ozkurt, MD and team at the Kartal Training and Research Hospital, Turkey performed a prospective, randomized study to compare the effects of dorzolamide-timolol combination and brimonidine on intraocular pressure (IOP) after phaco.

The study included 69 eyes of 43 patients undergoing phacoemulsification and foldable IOL implantation. Patients were randomly assigned to one of three treatment groups preoperatively; group A (n=23) received one drop of dorzolamide-timolol fixed combination and group B (n=23) received one drop of brimonidine tartrate 0.2% immediately after surgery. Group C (n=23), in which patients received no treatment, was the control group. IOP was measured by Goldmann applanation tonometry six and 24 hours after surgery.

Six hours after surgery, the mean IOP was significantly lower in group A (16.3±2.9 mmHg) than in groups B (20.6±2.9 mmHg) and C (24.6±5.4 mmHg). Twenty-four hours after surgery, the mean IOP remained lowest in group A (14.1±2.8 mmHg) and was higher in group C (19.8±4.7 mmHg) than in group B (17.5±2.7 mmHg).

The researchers therefore demonstrated that prophylactic treatment with dorzolamide-timolol fixed combination was more effective than brimonidine in reducing IOP six hours and 24 hours after cataract surgery.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
© 2025 MJH Life Sciences

All rights reserved.